Who
Coastlands Capital LP
10% owner
Company insider
Files Form 4 as: 10% owner, Adial Pharmaceuticals; 10% owner, Pasithea Therapeutics; 10% owner, Eloxx Pharmaceuticals.
In numbers
- Trades disclosed
- 16
- Buys
- 6
- Sells
- 0
- Bought
- $319K
- Sold
- $0
- Companies
- 3
- Companies where not an officer
- 3
- First trade
- 27 May 2026
- Last trade
- 16 Jul 2026
- Last filed
- 16 Jul 2026
Companies traded
Activity over time
1 Jun – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 16 Jul 2026filed 16 Jul 2026 | ADIL Adial PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $3,3911,233 at $2.75 | filing |
| 16 Jul 2026filed 16 Jul 2026 | ADIL Adial PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $3,3911,233 at $2.75 | filing |
| 14 Jul 2026filed 16 Jul 2026 | ADIL Adial PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $5,3002,000 at $2.65 | filing |
| 14 Jul 2026filed 16 Jul 2026 | ADIL Adial PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $5,3002,000 at $2.65 | filing |
| 10 Jul 2026filed 13 Jul 2026 | ADIL Adial PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $4,5901,700 at $2.70 | filing |
| 10 Jul 2026filed 13 Jul 2026 | ADIL Adial PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $4,5901,700 at $2.70 | filing |
| 9 Jul 2026filed 13 Jul 2026 | ADIL Adial PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $28K10,053 at $2.79 | filing |
| 9 Jul 2026filed 13 Jul 2026 | ADIL Adial PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $28K10,053 at $2.79 | filing |
| 29 Jun 2026filed 1 Jul 2026 | ADIL Adial PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $65K25,000 at $2.60 | filing |
| 29 Jun 2026filed 1 Jul 2026 | ADIL Adial PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $65K25,000 at $2.60 | filing |
| 17 Jun 2026filed 22 Jun 2026 | KTTA Pasithea TherapeuticsBiotechnology | SEC FORM 4 Bought | $53K100,000 at $0.53 | filing |
| 17 Jun 2026filed 22 Jun 2026 | KTTA Pasithea TherapeuticsBiotechnology | SEC FORM 4 Bought | $53K100,000 at $0.53 | filing |
| 27 May 2026filed 29 May 2026 | ELOX Eloxx PharmaceuticalsBiotechnology | SEC FORM 4 Code J | —1,250,000 at $0.00 | filing |
| 27 May 2026filed 29 May 2026 | ELOX Eloxx Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code J | —1,250,000 at $0.00 | filing |
| 27 May 2026filed 29 May 2026 | ELOX Eloxx Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code J | —1,250,000 at $0.00 | filing |
| 27 May 2026filed 29 May 2026 | ELOX Eloxx PharmaceuticalsBiotechnology | SEC FORM 4 Code J | —1,250,000 at $0.00 | filing |
News
Pasithea Therapeutics Announces Positive PAS-004 Clinical Data from Phase 1 Advanced Cancer Study Presented at ESMO Congress 2026KTTA · manilatimes.net · 23 Oct 2026Adial Pharmaceuticals Appoints David Rubenstein, M.D., Ph.D., as Chief Scientist to Advance its Colon-Targeted AhR Agonist, AT177, for Ulcerative ColitisADIL · manilatimes.net · 16 Oct 2026
0 headlines in the last 90 days name Coastlands Capital LP; 2 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.